As sustainability becomes a pressing global imperative, Cohance Lifesciences stands out as a shining example of environmentally conscious manufacturing and innovation in the pharmaceutical industry. The company, which rebranded from RA Chem Pharma Ltd. in 2022, has made significant strides in integrating sustainable practices into its operations, ensuring that its growth aligns with environmental stewardship and social responsibility.
A Commitment to Quality & Compliance
Cohance Lifesciences has established itself as a formidable player in the Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) sectors. The company operates five manufacturing units and boasts a portfolio of over 50 commercial APIs, catering to a diverse range of therapeutic applications. Notably, the API Unit-I in Jaggaiahpet successfully passed the EU GMP inspection in April 2022, receiving a “Certificate of GMP Compliance” for all inspected drug substances. Similarly, the CRBio facility achieved a commendable result in the US FDA inspection in January 2023, with zero observations reported, underscoring the company’s unwavering commitment to quality and compliance.
Sustainability Initiatives: A Holistic Approach
Cohance Lifesciences recognizes that its operations have a significant environmental impact, from resource consumption to carbon emissions. As a responsible manufacturer, the company is dedicated to optimizing resource use through various initiatives aimed at energy conservation, water conservation, green chemistry, solvent recycling, waste reduction, and process efficiency improvement. The Chief Operations Officer, Mr. Sunil Govind Uttarwar, emphasizes the importance of investing in new technologies and efficient processes to minimize the carbon footprint, showcasing a proactive approach to sustainability.
The company’s commitment to sustainability is further reflected in its certifications. API Unit-I has been certified in ISO 14001:2015 and 45001:2018, with zero non-conformities noted, while Cohance Lifesciences has also achieved ISO 9001-2015 certification. These accolades not only validate the company’s operational excellence but also reinforce its dedication to maintaining high environmental and quality standards.
Innovative Research & Development
Cohance Lifesciences is not just focused on compliance and sustainability; it is also at the forefront of innovation. The company has invested in a robust R&D infrastructure, employing over 75 scientists dedicated to developing complex chemistries and advanced formulations. This commitment to research enables Cohance to handle multi-step complex chemistry and cater to the evolving needs of the pharmaceutical market, particularly in oncology and other high-demand therapeutic areas.
The establishment of dedicated facilities for potent kilo laboratory and modern R&D further enhances Cohance’s capabilities, allowing for timely scaling of production while meeting stringent regulatory requirements. This strategic focus on R&D positions Cohance as a leader in the CDMO space, capable of delivering high-quality products from concept to commercialization.
Global Reach & Market Impact
Cohance Lifesciences serves customers across more than 60 countries, with a significant market share in various key molecules. The company’s strategic partnerships and backward integration efforts have enabled it to secure a robust supply chain, ensuring the availability of high-quality APIs and formulations to meet global demand. With a commitment to enhancing the quality of life for millions of patients, Cohance aims to co-create a top-tier CDMO and merchant API platform, solidifying its position as a partner of choice for global pharmaceutical and specialty chemical customers.
A Vision for the Future
As Cohance Lifesciences continues to navigate the complexities of the pharmaceutical landscape, its commitment to sustainability, quality, and innovation remains unwavering. The company’s proactive approach to reducing its environmental impact while delivering high-quality products positions it as a leader in the industry. With a clear vision for the future, Cohance Lifesciences is not only transforming its operations but also setting industry-leading standards that will inspire others to follow suit.
In conclusion, Cohance Lifesciences exemplifies how a pharmaceutical company can thrive while prioritizing sustainability and social responsibility. As the industry evolves, Cohance’s initiatives and achievements will undoubtedly serve as a model for others, proving that it is possible to achieve business success while making a positive impact on society and the environment.
– Ennen
More articles on Suven Cohance Merger
